APR 11, 2018 7:00 AM PDT

Breast Cancer Therapy Effects: Heart Damage and Mortality Risk Study Surprise Finding

WRITTEN BY: Mauri Brueggeman

Breast cancer, as noted by German Research Group DKFZ, is the second most frequent cancer worldwide and the number one cancer in women.  Early diagnosis and aggressive therapies have lowered the risk of dying of this disease.  However, as a result of the treatments involved, women are subject to cancer related side effects including heart damage.  Some generally accepted causes include pre-existing heart risk factors like hypertension or cholesterol levels unmonitored during breast cancer treatment and exposure during treatments like chemotherapy or radiation therapy.  More studies show side effects can include abnormal rhythms, valve issues or even failure over time due to a weakening of the heart.  There is extensive literature to demonstrate this.  However, there have been few studies to show if breast cancer therapy related side effects contribute to overall mortality of patients now that there are more women surviving their cancer. 

The German Cancer Research Center, DKFB, set out to evaluate data from 350,000 patients on the US cancer registry diagnosed with breast cancer in the years 2000 to 2011 and having received chemotherapy or radiation therapy.  It was published in the European Heart Journal in April 2018.  They hypothesized that when compared to healthy women not having undergone cancer treatments, the risk of dying of a common treatment side effect, like heart disease, would be increased.  The researchers were surprised by what they found. 

While the treated cancer survivors may have incurred side effects commonly studied after traditional breast cancer therapies, their long-term mortality risk from heart disease was not higher than the average female population.  They evaluated chemotherapy and radiation therapy separately and came to the same conclusions.  The authors postulated a few possible reasons.  The first is that clinical trials require specific criteria to participate whereas the cancer registry includes all cancer patients affected; there is a lot more variability and is a better representation of the population overall, which aligns with the broader female population.  Trial participants are a narrower group.  Secondly, and encouraging, is the attribution to good risk management by providers and hospitals to mitigate the known risks of breast cancer side effects through creative assessment teams.  The example provided by the researchers was the utilization of cardio-oncology units where an individual’s risk for heart disease due to treatment is already taken into account and part of the monitoring process for that patient.  The combination of specialties allows for comorbidity evaluation and planning for treatments.   

This observational analysis does not mean that breast cancer patients are not at risk of being affected by treatment side effects, nor that they should be minimized.  More research and large scale longitudinal studies should be completed to follow breast cancer patients and survivors; however, this study provides hope for the many survivors that after treatment the likelihood of living fully is very real and possible.

Sources: European Heart Journal, German Cancer Research Center (DKFZ), Revista Española De Cardiologia (Eng Version)-Interventional Cardiology,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
AUG 24, 2021
Technology
CRISPR Helps Identify New Therapeutic Target for Leukemia
AUG 24, 2021
CRISPR Helps Identify New Therapeutic Target for Leukemia
Researchers may have found a new druggable target in patients with acute myeloid leukemia (AML), thanks to a CRISPR scre ...
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
OCT 18, 2021
Cancer
The History of Immunotherapy: Toxins, Targets & T Cells
OCT 18, 2021
The History of Immunotherapy: Toxins, Targets & T Cells
Cancer immunotherapy, a treatment that directly enhances a patient’s immune system, is typically perceived as a mo ...
DEC 27, 2021
Cancer
Improving Immunotherapy with a Novel Nanoparticle
DEC 27, 2021
Improving Immunotherapy with a Novel Nanoparticle
Malignant pleural effusion (MPE) occurs in cancer patients experiencing a buildup of fluid and tumor cells in the pleura ...
DEC 31, 2021
Cell & Molecular Biology
Cells Found to Release Super Small Bioactive Particles Called Supermeres
DEC 31, 2021
Cells Found to Release Super Small Bioactive Particles Called Supermeres
We know that cells are constantly secreting molecules that can have many different biological impacts; the term extracel ...
JAN 06, 2022
Cancer
Breakthrough COVID Cases Cause Concern for Cancer Patients
JAN 06, 2022
Breakthrough COVID Cases Cause Concern for Cancer Patients
As we enter the third year of the COVID-19 pandemic, we continue to learn more about the respiratory virus leading to a ...
Loading Comments...